Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Jeffrey L. Cleland"'
Autor:
Caden M. Henningfield, Neelakshi Soni, Ryan W. Lee, Rishi Sharma, Jeffrey L. Cleland, Kim N. Green
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-14 (2024)
Abstract Background In Alzheimer’s disease (AD), microglia surround extracellular plaques and mount a sustained inflammatory response, contributing to the pathogenesis of the disease. Identifying approaches to specifically target plaque-associated
Externí odkaz:
https://doaj.org/article/3f0524a04e284b6595db180cca11d16b
Autor:
Hiroki Tsujinaka, Jie Fu, Jikui Shen, Yun Yu, Zibran Hafiz, Joshua Kays, David McKenzie, Delia Cardona, David Culp, Ward Peterson, Brian C. Gilger, Christopher S. Crean, Jin-Zhong Zhang, Yogita Kanan, Weiling Yu, Jeffrey L. Cleland, Ming Yang, Justin Hanes, Peter A. Campochiaro
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Neovascular age-related macular degeneration and diabetic retinopathy are currently treated with repeated intravitreous injections of VEGF neutralizing proteins. Here the authors develop a microparticle-loaded tyrosine kinase inhibitor therapy, which
Externí odkaz:
https://doaj.org/article/2ec68ea8afa548e39d54ab7c4b1ff7de
Autor:
Naze G. Avci, Tony Wu, Susan E. Alters, Emily Zhang, Jinping Liu, Dong Huang, Natacha Le Moan, Jeffrey L. Cleland
Publikováno v:
Cancer Research. 83:LB208-LB208
Tumor-associated macrophages (TAMs) play a role in cancer progression and are associated with Sorafenib resistance in hepatocellular carcinoma (HCC)1. D-4559 is a new potent macrophage switching nanomedicine technology that selectively inhibits VEGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f3c5bf35d771119094d3153f5d85f16
https://doi.org/10.1158/1538-7445.am2023-lb208
https://doi.org/10.1158/1538-7445.am2023-lb208
Publikováno v:
Alzheimer's & Dementia. 16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00f31e67df899b743fe49b0234633b6e
https://doi.org/10.1002/alz.040661
https://doi.org/10.1002/alz.040661
Autor:
Rajsekar Rami Reddy, Rangaramanujam M. Kannan, Rishi Sharma, Zhi Zhang, Sujatha Kannan, Jeffrey L. Cleland, Anjali Sharma, Siva P. Kambhampati
Publikováno v:
Bioengineering & Translational Medicine
Dendrimer‐N‐acetyl cysteine (D‐NAC) conjugate has shown significant promise in multiple preclinical models of brain injury and is undergoing clinical translation. D‐NAC is a generation‐4 hydroxyl‐polyamidoamine dendrimer conjugate where N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95e380fe2b07ac1db3ef3dab88493ae9
http://europepmc.org/articles/PMC6063872
http://europepmc.org/articles/PMC6063872
Autor:
Nathan C Geething, Wayne To, Benjamin J Spink, Michael D Scholle, Chia-wei Wang, Yong Yin, Yi Yao, Volker Schellenberger, Jeffrey L Cleland, Willem P C Stemmer, Joshua Silverman
Publikováno v:
PLoS ONE, Vol 5, Iss 4, p e10175 (2010)
While the majority of current diabetes treatments focus on reducing blood glucose levels, hypoglycemia represents a significant risk associated with insulin treatment. Glucagon plays a major regulatory role in controlling hypoglycemia in vivo, but it
Externí odkaz:
https://doaj.org/article/5d3650dde8fd4000aca777c7b8cd018c
Autor:
Santiago Appiani, Patrick McConville, Minghao Sun, Rishi Sharma, Susan E. Alters, Richard Coelho, Jeffrey L. Cleland
Publikováno v:
Clinical Cancer Research. 27:PO-097
Previous studies have demonstrated hydroxyl dendrimers (HDs) are selectively taken up by tumor associated macrophages (TAMs) after a single administration. HDs have also been observed to cross the blood brain barrier in six animal species including d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::824873fb1960537853a084dcd29bdf48
https://doi.org/10.1158/1557-3265.radsci21-po-097
https://doi.org/10.1158/1557-3265.radsci21-po-097
Autor:
Eric Humphriss, George M. Bright, Huong Jil Nguyen, Douglas Rogers, Jerome A. Moore, David Ng, Gad B. Kletter, Wayne V. Moore, Bradley S. Miller, Jeffrey L. Cleland
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 101:1091-1097
Context: Somavaratan (VRS-317) is a long-acting form of recombinant human GH under development for children and adults with GH deficiency (GHD). Objectives: To determine the optimal somavaratan dose regimen to normalize IGF-1 in pediatric GHD and to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6ffd7d57a18b4f657bcd1d82f9453ad
https://doi.org/10.1210/jc.2015-3279
https://doi.org/10.1210/jc.2015-3279
Abstract 679: Selective targeting of immunosuppressive tumor macrophage from systemic administration
Autor:
Jeffrey L. Cleland, Lindsay Usher, Santiago Appiani, Emily O’Koren, Kannan Rangaramanujam, Rishi Sharma
Publikováno v:
Cancer Research. 80:679-679
Macrophage in tumors in the M2 immunosuppressive state have been shown to play a role in reducing the effectiveness of immunotherapy and facilitating metastases formation. Many current approaches to targeting macrophage are not selective to the tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c50a3959f05354c68270a7fb35fdd71
https://doi.org/10.1158/1538-7445.am2020-679
https://doi.org/10.1158/1538-7445.am2020-679
Autor:
Beverly M. K. Biller, Kevin C.J. Yuen, Gerard S. Conway, Timothy S. Bailey, George M. Bright, Jeffrey L. Cleland, George R. Merriam, Eric Humphriss, Jerome A. Moore, Amir H. Hamrahian, Mark Kipnes, Vera Popovic
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Background: Administration of daily recombinant human GH (rhGH) poses a considerable challenge to patient compliance. Reduced dosing frequency may improve treatment adherence and potentially overall treatment outcomes. Objectives: This study assessed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::514d082127552adc95061b34658a26b4
https://doi.org/10.1210/jc.2013-1437
https://doi.org/10.1210/jc.2013-1437